Bundangseoul national unversity hospital
Sŏngnam, GyeonggiDo, South Korea
NCT Number: NCT04473417
This is the phase I study to evaluate the pharmacokinetics and safety of DA-2811 and Forxiga® after a single oral dose in healthy volunteers.
The study will also compare the pharmacokinetics and safety profiles of DA-2811 under fasting and fed states in healthy subjects.
Looking for future studies?
Notify Me19 year–45 year
All sexes
Interventional
Phase 1
Sŏngnam, GyeonggiDo, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single dose administration after 10hr fasting
single dose administration after 10hr fasting
Time frame: pre-dose~48 hours post-dose
Area under the plasma concentration-time curve from time zero to time the last quantifiable time
Time frame: pre-dose~48 hours post-dose
Maximum plasma concentration
Time frame: pre-dose~48 hours post-dose
Area under the plasma concentration versus time curve from time zero to extrapolated infinite time (0 - ∞)
Time frame: pre-dose~48 hours post-dose
Time to reach maximum plasma concentration following drug administration
Time frame: pre-dose~48 hours post dose
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Dong-A ST Co., Ltd.
Industry
An Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2811 in Healthy Subjects
Acronym: DA-2811
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details